Troy Bremer, Ph.D.

CSO and Founder of PreludeDx

2:00 DCISionRT—Background of Assay, Supporting Evidence/Data, Outcomes

Jim Pellicane, MD

  • Breast Cancer Surgeon
  • Director of Breast Oncology
  • Bon Secours Cancer Institute
15:50 Introduction
16:16 Surgeon’s clinical dilemma to assessing risk in DCIS patients
22:57 Why is ER not a good indicator of risk assessment?
24:13 Why is patient age is no an independent predictor of risk?
25:23 What are side effects of RT, especially for younger patients?
26:20 What are the surgical options and decisions impacted by RT?
27:11 Case Studies
36:00 Personal lessons learned
39:18 What is the impact of hormone therapy on DCISionRT score?

Christy Kesslering, MD

  • Radiation Oncologist, Breast Cancer Specialist
  • Radiation Oncology Consultants
  • Northwester Medicine Radiation Oncology, Warrenville
39:55 Introduction
40:04 Clinical dilemma: Am I seeing all the patients? When do surgeons refer patients to me?
50:04 Why Tumor Grade and RTOG9804 Classification is not always the best indicator of Risk?
51:23 Case Studies
52:15 Clinical Application of DCISionRT testing for DCIS patients
53:08 Why should DCISionRT be ordered for every patient?
55:20 How genomic testing can help guide intensification and de-escalation of RT
56:52 Challenges and solution insights for radiation oncologists to use genomics in DCIS

Q and A with the Panelists

59:22 Why is 0.8 that DCISionRT common score? Answered by Christy
1:00:46 Turn-around-time and Billing. Answered by Dr. Pellicane
1:01:43 How do you build consensus/buy-in within your medical group/colleagues to implement a DCIS protocol between radiation oncologists and surgeons? Answered by Dr. Pellicane and Dr. Kesslering
1:03:20 Why order DCISionRT on all my DCIS patients? Answered by Dr. Kesslering
1:04:28 What are the results and implications of interaction studies between DCISion Score and RT? Answered by Dr. Bremer
105:59 Conclusion